TwoStep Therapeutics, a biotechnology company developing innovative, first-in-class, multispecific targeted peptide conjugate therapies for solid tumors, will present at the 5th Novel Conjugates Summit in Boston, Massachusetts, March 17–19, 2026.
Oral Presentation:
Title: Multispecific Drug Conjugates Combat Tumor Heterogeneity & Resistance
Date and Time: Wednesday, March 18, 2026, at 4:30 p.m. ET
Invited Speaker: Caitlyn Miller, PhD, CEO & Co-Founder of TwoStep Therapeutics
About TwoStep Therapeutics
TwoStep Therapeutics is a biotechnology company developing a pipeline built around a unique tumor-targeting polyspecific integrin-binding peptide (PIP) that can selectively bind several targets that are highly expressed on solid tumors. This multi-targeting feature enables the agent’s broad applicability to a wide range of tumor types and patient populations, overcoming the limitations of single-antigen targeting approaches. The company has leveraged this technology to create a pipeline of targeted cancer therapies for cytotoxic drug delivery and radioligand therapy.
More information: https://twosteptx.com/
Contact: media@twosteptx.com